ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

doi:10.1200/JCO.23.01134

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2024

Arrillaga-Romany Isabel, Gardner Sharon L, Odia Yazmin, Aguilera Dolly, Allen Joshua E, Batchelor Tracy, Butowski Nicholas, Chen Clark, Cloughesy Timothy, Cluster Andrew, de Groot John, Dixit Karan S, Graber Jerome J, Haggiagi Aya M, Harrison Rebecca A, Kheradpour Albert, Kilburn Lindsay B, Kurz Sylvia C, Lu Guangrong, MacDonald Tobey J, Mehta Minesh, Melemed Allen S, Nghiemphu Phioanh Leia, Ramage Samuel C, Shonka Nicole, Sumrall Ashley, Tarapore Rohinton S, Taylor Lynne, Umemura Yoshie, Wen Patrick Y

Abstract excerpt

PURPOSE: Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), a first-in-class imipridone, in recurrent H3 K27M-mutant DMG. METHODS: Fifty patients (pediatric, n = 4; adult, n = 46) with recurrent H3 K27M-mutant DMG who received oral ONC201 monotherapy in four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Glioma

Share to Histones

Share to Neoplasm Recurrence, Local

Share to Pyridones

Share to Pyrimidines

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 38335473
DOI: 10.1200/JCO.23.01134
PMCID: PMC11095894

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.PMID 38335473Read ↗

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read ↗

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.Semantic proximity Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.Semantic proximity Read ↗

Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.Semantic proximity Read ↗

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.Semantic proximity Read ↗

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.Semantic proximity Read ↗

H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.Semantic proximity Read ↗

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.